- National Quality Forum NQF 1879 Measurement Year 2012 to 2014
- Adherence to Antipsychotic Medications for Schizophrenia
- Antipsychotic Medications
- Psychosis Drugs
- Quality Healthcare
- Ambulatory Care
- NQF Measures
- Medication Measures
- Healthcare Processes
- CMS Special Innovation Project
Adherence to Antipsychotic Medications for Schizophrenia NQF 1879
This dataset contains the information on the measure “Adherence to Antipsychotic Medications for Schizophrenia NQF (National Quality Forum) 1879” which is the Percentage of individuals at least 18 years of age with schizophrenia or schizoaffective disorder who had at least two prescription drug claims for antipsychotic medications and had a Proportion of Days Covered (PDC) of at least 0.8 for antipsychotic medications during the measurement period (12 consecutive months of the year 2012.
Get The Data
- ResearchNon-Commercial, Share-Alike, Attribution Free Forever
- CommercialCommercial Use, Remix & Adapt, White Label Log in to download
CMS (Centers for Medicare & Medicaid Services) has contracted with FMQAI (Florida’s Medicare Quality Improvement Organization) to provide services for the Medication Measures Special Innovation Project, the purpose of which is to develop measures that can be used to support quality healthcare delivery to Medicare beneficiaries. The project currently has a portfolio of eight NQF-Endorsed measures for the ambulatory care setting, NQF 0543, NQF 0545, NQF 0555, NQF 0556, NQF 1879, NQF 1880, NQF 2362, NQF 2363, NQF 2379, NQF 2467, NQF 2468.
Quality health care is a high priority for the President, the Department of Health and Human Services (HHS), and the Centers for Medicare & Medicaid Services (CMS). CMS implements quality initiatives to assure quality health care for Medicare Beneficiaries through accountability and public disclosure. CMS uses quality measures in its various quality initiatives that include quality improvement, pay for reporting, and public reporting.
Quality measures are tools that help to measure or quantify healthcare processes, outcomes, patient perceptions, and organizational structure and/or systems that are associated with the ability to provide high-quality health care and/or that relate to one or more quality goals for health care. These goals include effective, safe, efficient, patient-centered, equitable and timely care.
CMS (Centers for Medicare & Medicaid Services) has contracted with FMQAI (Florida’s Medicare Quality Improvement Organization) to provide services for the Medication Measures Special Innovation Project, the purpose of which is to develop measures that can be used to support quality healthcare delivery to Medicare beneficiaries.
The key objectives of the project are to:
– Develop new and maintain previously developed medication measures with the potential for National Quality Forum (NQF) endorsement.
– Adapt/specify existing NQF-endorsed medication measures and develop new measures for implementation in CMS reporting programs, such as
– Hospital Inpatient Quality Reporting (IQR) Program
– Hospital Outpatient Quality Reporting (OQR) Program
– Physician Quality Reporting System (PQRS)
– Others as directed by CMS, such as long-term care settings and ambulatory care settings.
– Continue to develop new medication measures that address the detection and prevention of adverse medication-related patient safety events that can be used in future Quality Improvement Organization (QIO) Statements of Work and in CMS provider reporting programs; and
– Identify and specify up to five new adverse event measures (non-medication-related) that could be used in future QIO programs and CMS provider reporting programs in the hospital setting (inpatient and/or emergency department).
In addition to maintenance of previously developed medication measures, the new measures to be developed under this special project support QIO patient safety initiatives by addressing topics, such as the detection and prevention of medication errors, adverse drug reactions, and other patient safety events. Under this Special Innovation Project, existing measures, as well as new measures, are being refined and specified for implementation in provider reporting programs.
The project currently has a portfolio of eight NQF endorsed measures for the ambulatory care setting, five of which (i.e., NQF 0545, NQF 0555, NQF 0556, NQF 2467, NQF 2468) are undergoing NQF comprehensive review and have received recommendations for re-endorsement. In addition, one measure (i.e., NQF 2379) for the ambulatory care setting and two electronic clinical quality measures (i.e., NQF 2362 and NQF 2363) for the inpatient care setting have been submitted to NQF and have received recommendations for endorsement.
– NQF 0543: Adherence to Statin Therapy for Individuals with Coronary Artery Disease
– NQF 0545: Adherence to Statins for Individuals with Diabetes Mellitus
– NQF 0555: INR Monitoring for Individuals on Warfarin
– NQF 0556: INR for Individuals Taking Warfarin and Interacting Anti-infective Medications
– NQF 1879: Adherence to Antipsychotic Medications for Individuals with Schizophrenia
– NQF 1880: Adherence to Mood Stabilizers for Individuals with Bipolar I Disorder
– NQF 2362: Glycemic Control – Hyperglycemia
– NQF 2363: Glycemic Control – Severe Hypoglycemia
– NQF 2379: Adherence to Antiplatelet Therapy after Stent Implantation
– NQF 2467: Adherence to ACEIs/ARBs for Individuals with Diabetes Mellit
– NQF 2468: Adherence to Oral Diabetes Agents for Individuals with Diabetes Mellitus
The maintenance of these measures requires the specifications to be updated annually.
– Measure Description: Percentage of individuals at least 18 years of age as of the beginning of the measurement period with schizophrenia or schizoaffective disorder who had at least two prescription drug claims for antipsychotic medications and had a Proportion of Days Covered (PDC) of at least 0.8 for antipsychotic medications during the measurement period (12 consecutive months).
– Measure Updates – Adherence to Antipsychotic Medications for Schizophrenia NQF 1879:
– 2011 Updates:
– Updated NDCs as of October 28, 2011.
– Added new 2011 CPT visit type codes, 99224-99226.
– Added new 2011 CPT J-codes for depot injections, paliperidone (J2426), and updated olanzapine (J2358).
– Updated ICD-9-CM and ICD-10-CM diagnosis codes with 2011 changes for dementia to be excluded. Added missing fifth digits to 290.1, 290.2, 290.4, and 294.1. Added new code V40.31.
– 2012 Updates:
– Updated NDCs as of October 31, 2012.
– Harmonized measure with NCQA 1936 for NQF submission and endorsement.
– Modified age requirement to at least 18 at the beginning of the measurement period.
– Modified codes used to identify encounter type to align with NCQA 1936.
– Removed the exclusion of depot injections following considerations for harmonization. Included antipsychotic depot drugs as part of the NDC list.
– 2013 Updates:
– Updated NDCs as of November 6, 2013.
– Added aripiprazole long-acting injection to Atypical Antipsychotic Medications.
– Updated the physician group attribution methodology and removed reference to UPIN, since UPIN is no longer used for the attribution.
– 2014 Updates:
– Updated NDCs as of December 10, 2014.
– Removed CPT visit type codes 90801, 90802, 90804-90819, 90821-90824, 90826-90829, 90857, and 90862, and added the replacement codes 90791, 90792, 90832, 90834, and 90837.
– Added CPT code 90839 for psychotherapy for crisis.
– Added CPT add-on codes for psychotherapy 90833, 90836, 90838, 90863, and 90840.
– Updated ICD-9-CM and ICD-10-CM diagnosis codes with 2014 changes for dementia to be excluded. Added new codes 294.20 and 294.21 for dementia and added code 292.82 for drug-induced persisting dementia. Removed V40.31.
About this Dataset
John Snow Labs; Centers for Medicare and Medicaid Services (CMS), Florida's Medicare Quality Improvement Organization (FMQAI);
|Source License URL|
|Source License Requirements||
Antipsychotic Medications, Psychosis Drugs, Quality Healthcare, Ambulatory Care, NQF Measures, Medication Measures, Healthcare Processes, CMS Special Innovation Project
National Quality Forum NQF 1879 Measurement Year 2012 to 2014, Adherence to Antipsychotic Medications for Schizophrenia
|National_Drug_Code||National Drug Code assigned to each drug||string||required : 1|
|Generic_Name||Drug's generic name/non-proprietary name||string||required : 1|
|Strength_of_Drug||Strength of dosage form||string||required : 1|
|Brand_Name||Drug's brand name/proprietary name/trade name||string||required : 1|
|Inactive_Date||Drug inactive date||date||-|
|Route_of_Administration||Route through which the drug is administered||string||required : 1|
|Dosage_Form||Dosage form in which the drug is supplied||string||required : 1|
|Drug_Pharmacological_Group||Pharmacologcal class of drug||string||required : 1|
|54868628000||ARIPIPRAZOLE||2 mg||ABILIFY||Oral||Tablet||PSYCHOTHERAPEUTIC DRUGS|
|63629338603||ARIPIPRAZOLE||2 mg||ABILIFY||Oral||Tablet||PSYCHOTHERAPEUTIC DRUGS|
|2411530||OLANZAPINE||5 MG||ZYPREXA||Oral||Tablet||ANTIPSYCHOTICS/ANTIMANIC AGENTS|
|2411501||OLANZAPINE||5 MG||ZYPREXA||Oral||Tablet||ANTIPSYCHOTICS/ANTIMANIC AGENTS|
|2411504||OLANZAPINE||5 MG||ZYPREXA||Oral||Tablet||ANTIPSYCHOTICS/ANTIMANIC AGENTS|
|2411533||OLANZAPINE||5 MG||ZYPREXA||Oral||Tablet||ANTIPSYCHOTICS/ANTIMANIC AGENTS|
|63402030410||LURASIDONE HCL||40 mg||LATUDA||Oral||Tablet||PSYCHOTHERAPEUTIC DRUGS|
|63402030430||LURASIDONE HCL||40 mg||LATUDA||Oral||Tablet||PSYCHOTHERAPEUTIC DRUGS|
|63402030810||LURASIDONE HCL||80 mg||LATUDA||Oral||Tablet||PSYCHOTHERAPEUTIC DRUGS|
|63402030830||LURASIDONE HCL||80 mg||LATUDA||Oral||Tablet||PSYCHOTHERAPEUTIC DRUGS|